Casdin Capital LLC Has $32.94 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Casdin Capital LLC decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 17.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 140,000 shares of the biopharmaceutical company's stock after selling 30,000 shares during the period. Alnylam Pharmaceuticals makes up about 2.2% of Casdin Capital LLC's portfolio, making the stock its 11th largest position. Casdin Capital LLC owned approximately 0.11% of Alnylam Pharmaceuticals worth $32,943,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in ALNY. Cetera Investment Advisers grew its stake in shares of Alnylam Pharmaceuticals by 66.3% in the 4th quarter. Cetera Investment Advisers now owns 4,770 shares of the biopharmaceutical company's stock worth $1,122,000 after acquiring an additional 1,902 shares in the last quarter. BOKF NA boosted its holdings in Alnylam Pharmaceuticals by 592.7% during the fourth quarter. BOKF NA now owns 381 shares of the biopharmaceutical company's stock worth $91,000 after purchasing an additional 326 shares during the last quarter. Bridger Management LLC grew its position in Alnylam Pharmaceuticals by 11.2% in the 4th quarter. Bridger Management LLC now owns 41,182 shares of the biopharmaceutical company's stock worth $9,691,000 after purchasing an additional 4,160 shares in the last quarter. Brevan Howard Capital Management LP lifted its position in shares of Alnylam Pharmaceuticals by 3.4% during the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock worth $314,000 after buying an additional 44 shares in the last quarter. Finally, Captrust Financial Advisors boosted its stake in shares of Alnylam Pharmaceuticals by 32.7% in the 4th quarter. Captrust Financial Advisors now owns 6,414 shares of the biopharmaceutical company's stock worth $1,509,000 after buying an additional 1,581 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 1,213 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares in the company, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,392 shares of company stock worth $1,875,627 over the last three months. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Up 5.5 %

Shares of NASDAQ:ALNY opened at $273.55 on Tuesday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The firm has a fifty day moving average of $248.81 and a 200 day moving average of $254.55. Alnylam Pharmaceuticals, Inc. has a 52-week low of $144.73 and a 52-week high of $304.39. The firm has a market capitalization of $35.58 billion, a PE ratio of -126.06 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. During the same period last year, the firm posted ($0.16) EPS. The business's revenue was up 20.2% on a year-over-year basis. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on ALNY. Sanford C. Bernstein cut their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. Royal Bank of Canada boosted their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a report on Friday, March 21st. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. Needham & Company LLC reissued a "buy" rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Finally, Citigroup lifted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $319.17.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.